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1. Introduction 
 
 
 
1.1. Diabetes mellitus-definition  
 
Diabetes mellitus is a group of metabolic diseases characterized by chronic 
hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both. A person with diabetes has high 
blood glucose either because they are not producing enough insulin, or because the 
body does not respond properly to insulin (1). 
 
1.2. Classification of diabetes 
 
Classification of diabetes includes etiological types and different clinical stages of 
hyperglycemia as suggested by Kuzuya and Matsuda (2). 
Four main etiological categories have been identified as diabetes type 1, type 2, other 
specific types, and gestational diabetes, as detailed in the WHO document (3). 
 
Type 1 diabetes is characterized by the processes of beta-cell destruction that may 
ultimately lead to a virtually complete lack of endogenous pancreatic insulin production. 
Exogenous insulin is required for survival. Type 1 diabetes is typical for young people, 
however it may occur at any age (4). People who have antibodies to pancreatic b-cells 
are likely to develop either typical acute onset or slow-progressive insulin-dependent 
diabetes (5,6). Today antibodies to pancreatic ß-cells are considered as a marker of 
type 1 diabetes, although such antibodies are not detectable in all patients.  
 
Type 2 diabetes is characterized by the disorders of insulin action and /or insulin 
secretion due to combination of genetic predisposition, unhealthy diet, physical 
inactivity, and increasing weight with a central distribution, resulting in complex 
pathophysiological processes. Early stages of type 2 diabetes are characterized by 
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insulin resistance causing excessive post-prandial hyperglycemia. This is followed by a 
deteriorating first-phase insulin response to increased blood glucose concentrations (7). 
Type 2 diabetes, comprising over 90% of adults with diabetes, typically develops after 
middle age. 
"Other specific types of diabetes," is the third category of diabetes which is mainly 
caused by a specific and identified underlying defect, such as genetic defects that may 
lead to rare forms of diabetes, as for instance MODY, or diseases of the exocrine 
pancreas (as a result of pancreatitis, trauma, or surgery of pancreas), or drug - 
chemically induced diabetes.  
 
Gestational Diabetes is a type of diabetes that constitutes any glucose perturbation 
that develops during pregnancy and withdraws after the delivery. Long-term follow-up 
studies that have been conducted over a period of more than 10 years reveal that 
approximately 70% of females with gestational diabetes will develop diabetes over time. 
In some cases, type 1 diabetes may be detected during pregnancy (8). 
 
 
1.3. Diagnostic criteria 
 
The current diagnostic criteria for Diabetes Mellitus are:  
 Fasting plasma glucose (FPG) value is ≥ 7.0 mmol/L (126 mg/dl). Fasting is defined as 
no caloric intake for at least 8h, or if the 
 Plasma glucose value 2 hours after 75g oral load glucose ( OGTT) ≥ 11.1 mmol/L 
(200mg/dl), or  
 In patient with classic symptoms of hyperglycemia or hyperglycemic crisis, casual 
plasma glucose value ≥ 11.1 mmol/L (200 mg/dl) , or 
 A1c ≥ 6.5%. The test should be performed in a laboratory using a method that is NGSP 
certified and standardized to the DCCT assay (3,9-11). 
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Traditionally, diagnosis of diabetes was based on symptoms due to hyperglycaemia, but 
during the last decades much emphasis has been placed on the need to identify 
diabetes and other forms of glucose abnormalities in asymptomatic subjects. In 
asymptomatic subjects, 
performing the test on one occasion is not enough to establish the diagnosis (i.e. basis 
to treat diabetes).  For clinical diagnosis the ADA recommends confirmation of a 
diagnosis of diabetes with a repeated FPG test on a separate day, especially for 
patients with borderline FPG results and patients with normal FPG levels for whom 
suspicion of diabetes is high (12). 
 
 
1.4. Burden 
 
The number of people with type 2 diabetes is increasing rapidly (13). 
Diabetes is one of the largest health emergencies of the 21st century. The World Health 
Organization (WHO) estimates that globally, high blood glucose is the third highest risk 
factor for premature mortality, after high blood pressure and tobacco use (14). 
Type 2 diabetes is a more common condition. In most countries, type 2 diabetes has 
increased alongside rapid cultural and social changes: aging populations, increasing 
urbanization, reduced physical activity, increased sugar consumption and less healthy 
diets with low fruit and vegetable intake (15). 
In 2013, over 382 million people worldwide have had diabetes; by 2035 this will rise 
to 592 million. In Europe, the number of people with diabetes in 2013 was 56 million 
with an overall estimated prevalence of 8.5%, a further increase of nearly 10 million 
people with diabetes is projected for the Europe by 2035  (16). 
In 2015, over 415 million people worldwide, or 8.8% of adults aged 20-79, are estimated 
to have diabetes. About 75% live in low- and middle-income countries. If these trends 
continue, by 2040 over 642 million people, or one adult in ten, will have diabetes. It is 
estimated that one third to one half of patients with type 2 diabetes or, 193 million are 
unaware of their condition and therefore untreated (17). 
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1.5. Complications 
 
People with diabetes are at higher risk of developing a number of disabling and life 
threatening health problems than people without diabetes. Consistently high blood 
glucose levels can lead to serious diseases causing the cardiovascular, 
cerebrovascular, peripheral artery disease, blindness, kidney failure, Charcot  joints, 
lower-limb amputation and autonomic dysfunction such as sexual impairment. People 
with diabetes are also at increased risk of developing infections, depression, anxiety 
and dementia. 
The growth in prevalence of type 2 diabetes in low- and middle-income countries means 
that without effective strategies to support better management of diabetes, it is likely 
that there will be large increases in the rates of these complications. Diabetes 
complications can be prevented or delayed by maintaining blood glucose, blood 
pressure and cholesterol levels as close to normal as possible. Many complications can 
be identified in their early stages by screening programs that allow treatment to prevent 
them becoming more serious (18). 
 
 
1.6. Cost of treating diabetes and its complications 
 
Treating diabetes has a cost of  hundreds of billions of dollars being spend each year. 
World treatment costs are growing more quickly than world population. The costs 
associated with diabetes include increased use of health services, loss of productivity, 
disability and the long term support needed to overcome diabetes related complications. 
As a result, diabetes imposes a large economic burden on individuals and families, 
national health systems and countries; it therefore represents a significant obstacle to 
sustainable economic development. However, the larger costs of diabetes arise from 
disability and life loss caused by its preventable complications, including heart, kidney, 
eye and foot disease (19). 
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Estimations are that globaly more than 80% of expenditures for medical care for 
diabetes are made in the world’s economically richest countries.  Less than 20% of 
expenditures are made in the middle- and low-income countries where  80% of people 
with diabetes are living. One country, the United States of America, is home to about 
8% of the world’s population  living with diabetes and spends more than 50% of all 
global expenditures for diabetes care. Europe accounts for 25% of diabetes-care 
spending. The remaining industrialized countries, such as Australia and Japan, account 
for most of the rest. In the world’s poorest countries, not enough is spent to provide 
even the least expensive life-saving diabetes drugs (20). 
The CODE 2 Study (21) was designed to measure the total healthcare costs for patients 
with type 2 diabetes in eight European countries using the same methodological 
approach. Patients from Belgium, France, Germany, Italy, the Netherlands, Spain, 
Sweden, and UK were included.  
The total healthcare cost for patients with diabetes in the eight countries amounted to 29 
billion Euro. Per capita cost varied from 1305 Euro per patient in Spain to 3576 Euro in 
Germany.  
The results from the CODE-2 Study have shown that the main cost-driver in diabetes is 
not the disease itself or the treatment of diabetes, but rather the complications caused 
by diabetes. In the study, patients were divided into complication-free, having 
microvascular complications only, having macrovascular complications only, or having 
both macro and microvascular complications. In these three groups, the relative costs 
were 1.7, 2.0, and 3.5 times higher than the costs among patients without complications 
(22).  
 
 
1.7. The natural history of type 2 diabetes, IFG and IGT 
 
The natural history of type 2 diabetes includes an asymptomatic phase- dysglycemia or 
prediabetes and preclinical phase or latent diabetes. 
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Type 2 diabetes is usually preceded by the „prediabetes“  or non-diabetic 
hyperglycemia or high risk for diabetes which includes impaired fasting glucose (IFG) 
values of 6.1-6.9 mmol/l. 5-10% of people with prediabetes will progress to diabetes 
within a year. However, some proportion of these patients will convert back to 
normoglycemia if there is early identification and intervention (40-70% relative risk 
reduction) (23-24). 
The pathogenesis of type 2 diabetes is not fully understood but involves gene-
environment interactions, which increase susceptibility to developing three metabolic 
defects: insulin resistance, insulin secretory defects, and increased glucose production 
by the liver. The primary defects are believed to be insulin resistance and early 
pancreatic β-cell susceptibility linked to predisposing genes, which are worsened by 
several factors, including obesity and physical inactivity (25,26).  
As the disease progresses, more global pancreatic defects result in increased hepatic 
glucose production. Persistent and increasing hyperglycemia further diminish the β-
cells’ capacity to secrete enough insulin to compensate sufficiently for the level of 
insulin resistance (27,28). 
This state, where abnormalities in glucose metabolism are present but elevation in 
glucose is below the cutoff point for establishing the diagnosis of type 2 diabetes, is 
referred to as pre-diabetes (29). ‘Pre-diabetes’, is a term that has not been unanimously 
supported by the scientists since diabetes will not necessarily developed in those with 
IGT or IFG. Both IFG and IGT are asymptomatic, intermediate states of abnormal 
glucose regulation that precede overt type 2 diabetes.  
IFG includes subjects with high fasting plasma glucose (FPG) concentration and normal 
response to a glucose load and impaired glucose tolerance (IGT) includes subjects with 
abnormal postprandial glucose excursion but normal FPG concentration (30). The IFG 
and IGT states are pathways that are correlated but may also appear independently. An 
individual falling into the IFG category on the fasting result may also have IGT on the 2-
h value or, indeed, diabetes. If an individual falls into two different categories, the more 
severe one applies. (31). 
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Both IGT and IFG are insulin-resistant states, but they differ in site of insulin resistance. 
Subjects with IFG predominantly have hepatic insulin resistance and normal muscle 
insulin sensitivity (32), while individuals with IGT have normal to slightly reduced hepatic 
insulin sensitivity and moderate to severe muscle insulin resistance (33).  
Global estimates of the burden of IFG and IGT are not available, but the number of 
people with IGT is likely to be even greater than the number with diabetes (34).   
The prevalence of IFG also varies among ethnic groups, but its prevalence consistently 
is lower than IGT in all populations. IGT and IFG also differ by the age and sex 
distribution. The prevalence of both categories increases with age, but under the age of 
55 years IGT is more frequent in women, while prevalence of IFG is twice as much 
higher in men than women (35). 
In the Hoorn Study, prospective cohort study of a white population aged 50 to 75 years, 
investigators found that patients with IFG and normal glucose tolerance had a similar 
risk of developing DM to those with IGT and normal fasting glucose (33.0 vs 33.8%) but 
incidence of diabetes,( 64.5%),  was strongly related to both impaired fasting and 
impaired postload glucose levels at baseline, during the 6-year follow-up (36). 
On average, both IFG and IGT are associated with a 20% increase in cardiovascular 
disease risk compared with normoglycemia (37).  
It has also been clearly established that microvascular complications are associated 
with dysglycemia (38): around 7.9% of people with dysglycemia had signs of retinopathy 
in the Diabetes Prevention Program (39,40); the prevalence of neuropathy is higher 
among people with IFG compared with those with normoglycemia (11.9% vs. 10.5%) 
(41,42) and people with IGT and/or IFG have a higher prevalence of chronic kidney 
disease compared with those with normoglycemia (17.7% vs. 10.6%) (43). Provided 
these facts and data, it is ascertained that IGT and IFG, compared with normoglycemia, 
have also been shown to be associated with higher medical costs (44, 45). 
Several cohort studies have shown a gradient of increasing mortality risk from 
normoglycemia to IFG, to IGT, and finally to diabetes. The relative risks for mortality 
among men and women, respectively, are approximately 21% and 8% higher for IFG 
and 51% and 60% higher for IGT than for normoglycemia (46-48). 
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1.8. Latent phase of diabetes 
 
Similarly to IFG and IGT, the early stages of type 2 diabetes after biologic onset are 
frequently asymptomatic; they can live for several years without showing any 
symptoms, during which time high blood glucose is silently damaging the body.  
They remain unaware of their condition for a long time because the symptoms are 
usually less marked than in type 1diabetes and may take years to be recognized. 
However, during this time the body is already being damaged by excess blood glucose. 
As a consequence, many people already have evidence of complications when they are 
diagnosed with type 2 diabetes 
It has been estimated by IDF that globally as many as 193 million people, or close to 
half (46.5%) of all people with diabetes, are unaware of their disease. The earlier a 
person is diagnosed and management initiated, the better the chances of preventing 
harmful and costly complications. The complications associated with diabetes are so 
varied that even when symptoms do exist, diabetes may not be thought to be the cause 
unless accurate and appropriate testing is carried out. Those who are undiagnosed will 
not be taking steps to manage their blood glucose levels or lifestyle, so many of them 
with undiagnosed diabetes already has complications such as chronic kidney disease 
and heart failure, retinopathy and neuropathy (49-51). 
The length of this asymptomatic period is less clear. No study has compared a screened 
with a comparable unscreened sample to determine the difference in the time at which 
diabetes is diagnosed. One group used an indirect approach to calculate this interval. 
After making assumptions about the rate of development of diabetic retinopathy early in 
diabetes, Harris and colleagues (52) estimated that the preclinical period lasted between 
10 and 12 years. According to this calculation, screening a previously unscreened 
population would detect diabetes an average of 5 to 6 years before clinical diagnosis. 
Even if this estimate is correct, however, it represents a mean value. Some people will 
have a longer and some a shorter asymptomatic period. The true mean length of this 
period and the distribution of its duration are unknown. Using a nonlinear model, 
Thompson et al. (53) reported estimates of 7–8 years. However, these estimates 
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represent mean values only, and the asymptomatic period may vary widely for 
individuals (54). 
Studies of people with newly conventionally diagnosed or screen-detected type 2 
diabetes provide evidence of early diabetes-related tissue damage during the preclinical 
phase. 
Studies of people with newly conventionally diagnosed or screen-detected type 2 
diabetes provide evidence of early diabetes-related tissue damage during the preclinical 
phase. 
 In the United Kingdom Prospective Diabetes Study (UKPDS), 50% of newly diagnosed 
diabetes cases had evidence of diabetes-related complications (55-57).  In the Hoorn 
screening study (58,59), the prevalences of myocardial infarction (13.3% vs. 3.4%) and 
ischemic heart disease (39.5% vs. 24.1%) were higher in screen-detected patients than 
in newly conventionally diagnosed patients, although the proportions with peripheral 
arterial disease were similar in both groups (10.6% vs. 10.2%). 
With regard to microvascular sequelae of diabetes, the Hoorn study showed a higher 
prevalence of retinopathy in screen-detected patients than in newly conventionally 
diagnosed patients (7.6 % vs. 1.9%), while the prevalence of impaired foot sensitivity 
was similar in both groups (48.1% vs. 48.3%). 
In the Anglo Danish Dutch Study of Intensive Treatment In people with screen-detected 
diabetes in primary care (ADDITION), screen-detected people had high estimated 10-
year absolute risks of coronary disease events (11% in women and 21% in men) (60) 
and composite cardiovascular disease (38.6% in men and 24.6% in women) (61).  
In US population-based surveys, compared with people without diabetes, those with 
undiagnosed diabetes had a significantly higher prevalence of neuropathy (11.6% vs. 
10.5%) (41, 42) and chronic kidney disease (41.7% vs. 10.6%) (43). 
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1.9. Screening for type 2 diabetes 
 
Strong evidence exists for the effectiveness of interventions to prevent type 2 diabetes 
mellitus among people with impaired glucose tolerance (IGT) (62,63). This evidence has 
led to recommendations to identify people with “dysglycemia” (IGT and/or IFG) and to 
implement diabetes prevention interventions (64). IGT/IFG and type 2 diabetes are part 
of a continuum; hence, the issues concerning screening for each are inseparable. It is 
justifiable to talk of and evaluate screening for both conditions together. Indeed, 
evidence from a modeling study suggests that combining screening for type 2 diabetes 
with screening for IGT is more likely to be cost-effective than screening for undiagnosed 
diabetes alone (65). The topic of screening for type 2 diabetes has been debated for 
some time and various reviews have been written (66-73), although they have focused 
on individual aspects of screening. Gaps regarding the collective issues associated with 
screening across the spectrum of dysglycemia and type 2 diabetes have not been fully 
described, nor have the implications for primary and secondary prevention. 
 
 
1.9.1 Definition of screening 
 
What is screening? The definition of the term screening is based on the WHO 
"Principles of Screening" document (74): 
“Screening is the process of identifying those individuals who are at 
sufficiently high risk of a specific disorder to warrant further investigation or 
direct action.” 
The definition goes on to say: 
“Screening is systematically offered to a population of people who have 
not sought medical attention on account of symptoms of the disease for which 
screening is being offered and is normally initiated by medical authorities and not by a 
patient's request for help on account of a specific complaint. The purpose of screening 
is to benefit the individuals being screened.” Screening may be defined as the use of 
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rapidly applied tests or examinations to presumptively identify individuals with 
unrecognized disease in order to permit timely intervention (74). 
The term diagnosis refers to confirmation of diabetes in people who have symptoms, or 
who have had a positive screening test. In diabetes, the screening test may be the 
diagnostic test, e.g. a fasting plasma glucose in someone who has symptoms or the first 
part of the diagnostic test if a second test, usually the OGTT is used to confirm the 
diagnosis in asymptomatic individuals. 
 
Screening for type 2 diabetes –The main reasons for the current interest in screening 
for type 2 diabetes are: there is a long, latent, asymptomatic preclinical period of up to 
12 years in which the condition can be detected (52,53,75,76), a substantial proportion 
of people with type 2 diabetes, up to 50% in most studies, remain undiagnosed for 
many years and a substantial proportion of newly referred cases of type 2 diabetes 
already have evidence of the micro-vascular complications of diabetes by the time of 
diagnosis (77-80). Primary care clinicians are encouraged to be more proactive in 
detecting and treating both diabetes and prediabetes (81).  
 
The updated standards of medical care of the American Diabetes Association (ADA) 
recommend testing adults of any age who are overweight or obese and have additional 
diabetes risk factors. They also recommended the FPG test for screening because it is 
easier and faster to perform, more convenient and acceptable to patients, and less 
expensive than other screening tests (82). 
 
1.9.2. Screening practices  
 
There are several potential approaches to screening for diabetes: 
• Screening the entire population is not recommended 
 
• Selective or targeted screening is performed in a subgroup of subjects whom have 
already been identified as being at relatively high risk in relation to age, body weight, 
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ethnic origin etc. Targeting high-risk patients is recommended, as there is no evidence 
of a direct benefit of routine population-based screening for type 2 diabetes. (83,84).  
 
• Opportunistic screening carried out at a time when people are seen, by health care 
professionals, for a reason other than the disorder in question. As screening should also 
be a systematic and continuous process opportunistic targeted screening might be a 
valuable screening method in primary care. This method entails screening high-risk 
individuals during usual care (85). The pragmatic nature of opportunistic targeted 
screening enables initiation of further diagnostic testing and treatment of newly 
diagnosed type 2 diabetes. 
These approaches are used alone or in combination. 
Screening yields are highly variable and dependent on the tests and cutoffs used. They 
also depend on the level of quality control and presence of adequate diagnostic 
resources in programs, as shown in an audit reporting the challenges to implement type 
2 diabetes screening in United Kingdom primary care (86). Current evidence does not 
support universal screening; however, data from the United Kingdom indicate that any 
well-conducted targeted screening may come close to universal screening (87). Most 
professional organizations advocate a selective and opportunistic approach in high-risk 
populations (88-91). 
Selective or targeted screening and opportunistic screening are not mutually exclusive 
since screening may be limited to those at highest risk. In opportunistic screening, the 
decision to initiate the health care encounter is made by the individual, although, for 
reasons not related to the condition for which screening is offered. This needs to be 
distinguished from screening programs in which the invitation to come forward and be 
screened is part of the program. 
There is also haphazard screening, characterized by a lack of a coherent 
screening policy. In such cases individuals may be invited to be screened 
irrespective of their risk (people in a supermarket, for example) or there may be no 
adequate explanation of the reasons for screening or no formal system of support for 
those taking part, whatever the outcome of their test. 
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1.9.3. Screening intervals 
 
There is no specific data that can be used to decide the optimal frequency of screening 
for type 2 diabetes or dysglycemia. An optimal interval between screening rounds would 
be one at which the prevalence of undiagnosed cases reaches the prevalence of such 
cases at the previous screening, and the cost-effectiveness is the same for each 
screening (54). The annual rate of progression from IFG and IGT to diabetes is 5%–
10%, which might argue for a short screening interval for people with dysglycemia (92). 
The annual progression from normoglycemia to diabetes, however, is in the range of 
0.6%–1.2%, depending on the population and age group studied. In a simulation 
quantifying the proportion of false positives with screening by OGTT, the percentage 
was 47.5% for annual repeat screening and 33.9% for a screening interval of 3 years 
(93). The US-based simulation reported that targeted screening for type 2 diabetes 
could be most cost-effective if repeated every 3–5 years (94). 
 
 1.9.4. Screening tests evaluation 
The sensitivity of a screening test is the proportion of people with the disorder who test 
positive on the screening tests. A highly sensitive screening test is unlikely to miss a 
subject with diabetes. 
The specificity of a screening test is the proportion of people who do not have the 
disorder who test negative on the screening tests. A highly specific test is unlikely to 
misclassify someone who does not have diabetes as having diabetes. Although it is 
desirable to have a test that is both highly sensitive and highly specific, this is usually 
not possible. In choosing a cut-off point a trade-off needs to be made between 
sensitivity and specificity, since increasing one reduces the other. The receiver operator 
characteristic (ROC) curve expresses this relationship. 
Validity is the extent to which the test reflects the true status of the individual. 
Reliability is the degree to which the results obtained by any given procedure can be 
replicated. 
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Reproducibility refers to obtaining similar or identical results on repeated 
measurements on the same subject. Screening tests must be shown to be valid, reliable 
and reproducible in the population in which screening is to take place. Uniform 
procedures and methods, standardized techniques, properly functioning equipment, and 
quality assurance are all necessary to ensure reliability and reproducibility. 
Predictive value relates to the probability that a person has or does not have the 
disorder given the result of the test.  
Positive predictive value is the probability of the disorder in a person with a positive 
test result and negative predictive value is the probability of a person not having the 
disorder when the test result is negative. 
The predictive value of a test is determined not only by the sensitivity and the specificity 
of the test, but also by the prevalence of the disorder in the population being screened. 
Thus, a highly sensitive and specific test will have a high positive predictive value in a 
population with a high prevalence of the disorder. This is part of the rationale for 
promoting selective or targeted screening. When the prevalence is low, as may be the 
case when the entire population (or the entire adult population) is screened, then the 
positive predictive value of the same test will be considerably lower. In this case, a high 
specificity drives a high positive predictive value. To avoid false positives it may be 
necessary to increase specificity at the expense of sensitivity. Screening tests may be 
used in parallel (i.e. a person is deemed to be likely to have a disorder if they test 
positive to either test). In this case the sensitivity and the negative predictive value are 
generally increased and the specificity and positive predicted values decreased. On the 
other hand, screening tests may be used in series (i.e. a person needs to be positive to 
both tests in order to be deemed likely to have the disorder). In this case the specificity 
and positive predicted value are generally increased and the sensitivity and negative 
predicted value decreased. Tests in series have been advocated in type 2 diabetes 
when, for example, a questionnaire may precede a fasting blood sample or OGTT and 
be used to exclude some individuals deemed to be at low risk of having the disorder. 
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1.9.5. Screening tests or tools 
 
Limited information is available regarding the optimal methods for diabetes screening. 
Therefore, it is uncertain how we should screen for diabetes (95-97). Many screening 
programmes combine population-based and targeted (directed at high-risk individuals) 
strategies in order to increase the yield (98). 
Previous studies have reported on the advantages and limitations of a number of 
screening tests and tools. These have included questionnaires/risk scoring tools and the 
following biochemical tests: urine glucose, random blood glucose, fasting plasma 
glucose, glycated hemoglobin (HbA1c), and the 75-g oral glucose tolerance test (OGTT) 
(67).  
Mainly, a stepped approach is chosen starting with a simple risk score to identify high-
risk individuals. The use of a risk score is attractive because it minimizes the number of 
persons who will attend glucose measurement and therefore reduces costs (99). 
 
Questionnaires/risk scores-Various instruments have been developed to identify 
people at high risk of having or developing type 2 diabetes or dysglycemia.  
These tools are based on risk factors that would help identify the minority of the 
population that accounts for the majority of people with type 2 diabetes and dysglycemia 
(89).  
The risk appraisal tools involve use of self-reported questionnaires (100-105), health 
service data (106-107) or collected anthropometric, lifestyle, or biochemical data (108–
127).  
Questionnaires, whose performance depends on the response rate, may create undue 
anxiety or false reassurance, but they are likely to be more acceptable, less costly, and 
less time-consuming to administer than blood glucose testing or anthropometric 
measurements for risk prediction. 
Use of existing health service data can limit the proportion of those who need to 
undergo blood glucose measurements to 20%–25% of the entire population, but this 
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tool may be limited by the availability of data on key variables. In general, including at 
least one blood glucose measurement improves the performance of a risk tool.  
If the risk tools (100-123) developed and validated on the basis of prevalence studies 
were used as part of a repeated screening program, performance of the tools would 
likely change.  
The most widely validated and used risk assessment tool is the Finnish risk score (102). 
It uses weighted data for 8 risk characteristics to calculate an overall score that predicts 
10-year absolute risk of type 2 diabetes. 
In summary, the existing simple tools to identify high-risk people are pragmatic. 
However, compared with OGTT, none of these tools are optimal. The efficiency of the 
tools may vary over time within a population (changing prevalence of risk factors), 
between populations and geographic areas, and they typically perform well in 
populations in which they were developed (128-129). 
 
 
Urine glucose-The sensitivity of urine glucose testing is low (16%–64%), and the 
positive predictive value ranges from 11% to 37% (54). Thus, glycosuria appears to be 
a poor screening instrument for diabetes; large proportions of individuals with diabetes 
would be misclassified and remain undetected. 
 
Random blood glucose-The use of random blood glucose as a screening tool is 
somewhat limited by its low screening performance (67). A large study comparing 
random blood glucose with OGTT for screening recommended a cost-effective random 
blood glucose cutoff of ≥6.9 mmol/L. At this level, random blood glucose exhibited 93% 
specificity and 41% sensitivity. In terms of identifying dysglycemia, the specificity was 
still high, at 94%, but sensitivity was only 23% (130).  
A recent expert panel recommended a random blood glucose cutoff of ≥7.2 mmol/L, 
which has a sensitivity of 63% and specificity of 87%, based on validation against OGTT 
(131). 
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Fasting plasma glucose-The fasting plasma glucose screening test for hyperglycemia 
may have modest sensitivity (67). A Korean study found that a fasting plasma glucose 
threshold of ≥7 mmol/L detected only 55.7% of people with diabetes based on diagnosis 
by OGTT, with 100% specificity (132). An optimal cutoff for fasting plasma glucose was 
>6.1 mmol/L with a sensitivity of 85.2%, but specificity was decreased to 88.5%. 
 A study of young African American patients with dysglycemia found fasting plasma 
glucose not sensitive for the diagnosis of IGT compared with OGTT (133). A fasting 
plasma glucose threshold of >5.6 mmol/L detected only 28.9% of IGT cases, whereas 
OGTT identified 87.4% of cases. 
 
Glycated hemoglobin- Even despite that fact that there is a need for approval in a 
wide range, the American Diabetes Association recently adopted HbA1c as a diagnostic 
test for diabetes at a threshold of ≥6.5% (134). This adoption was justified by the 
alignment of the associations between HbA1c and fasting plasma glucose with diabetes 
complications (particularly retinopathy) and the stronger correlation of HbA1c with risks 
of cardiovascular disease and all-cause mortality compared with fasting plasma glucose 
(135). 
However, the new American Diabetes Association criteria using HbA1c do not 
specifically define IFG and IGT categories but rather a “high-risk” category 
corresponding to an HbA1c between 5.7% and 6.4%. 
The performance of HbA1c ≥6.5% for type 2 diabetes diagnosis is variable in studies.  
In combination with either random blood glucose or fasting plasma glucose, HbA1c may 
add value in identifying the subgroups of individuals who need to undergo an OGTT 
(132). 
An effective international standardization of HbA1c is well under way (136–138). 
However, the costs and lack of availability of the test in low-resource settings remain 
high level concern (131). 
 
The 50-g oral glucose challenge test-An evaluation of the 50-g oral glucose challenge 
test as a screening tool for adults found areas under the receiver operating 
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characteristic curves of 0.90, 0.82, and 0.79 for detection of undiagnosed diabetes, 
undiagnosed diabetes or dysglycemia, and dysglycemia, respectively, by plasma 
glucose challenge test (139). This performance was unaffected by time of day or 
proximity to meal times and is superior to that of capillary glucose challenge test, 
plasma random blood glucose, capillary random blood glucose, and HbA1c. However, 
this study was limited by self-selection of participants (only black and white racial 
groups were included), lack of measures of intraparticipant variability, and validation in 
separate populations. 
 
Capillary blood testing: finger-prick point-of-care testing-The utility of capillary 
blood testing for diabetes screening is unclear. An Australian study found that point-of-
care capillary glucose testing underestimated blood glucose values compared with 
fasting plasma glucose. The areas under the receiver operating characteristic curves for 
prediction of dysglycemia and diabetes were 0.76 and 0.71 for point-of-care and 0.87 
and 0.81 for fasting plasma glucose, respectively (140). However, among Asian Indians 
(141), capillary random blood glucose cutpoints >6.0 mmol/L have reasonably good 
sensitivity (66.5%–70.5%) and specificity (65.5%–69.5%) for type 2 diabetes, IGT, and 
IFG screening. 
 
Combinations of tests-Screening tests, as mentioned above, may be combined to 
improve performance. In relation to type 2 diabetes this can be done using a series of  
tests (e.g. assessing risk by questionnaire followed by blood glucose measurement if a 
certain risk score is reached) or simultaneously (e.g. measurement of blood glucose 
and HbA1c at the same time). Combining the tests is more resource intensive, 
especially if applied sequentially. 
Tests performed in parallel using FPG and HbA1c or fructosamine have been reported 
to have sensitivity ranging from 40% to 83% and specificity of 83%-99%, depending on 
the cut off values chosen (54). Combining the modified ADA questionnaire and RCBG ³ 
6.7 mmol l-1 achieved a sensitivity of 58% and specificity of 94% (142). 
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An illustration of the effects of serial combination testing for a screening protocol which 
initially assessed risk factors, performed FPG in those at risk, then measured HbA1c in 
those with an FPG between 5.5 and 6.9 mmol l-1, and then tested with an OGTT those 
who had an HbA1c ³ 5.3%. This example illustrates that series of testing results in 
decreasing sensitivity, increasing specificity and PPV and reduces the number of people 
requiring definitive testing. 
Multivariate logistic regression modelling with derivation of a probability value is another 
approach to combining demographic, clinical and biochemical tests in screening for 
undiagnosed diabetes. Tabaei and Herman(143) combined age, sex, BMI, postprandial 
time and random capillary plasma glucose to calculate the probability of undiagnosed 
diabetes and therefore the need for an OGTT. The calculation can be performed on a 
hand held programmable calculator and had a sensitivity of 65%, specificity of 96% and 
PPV of 63%. 
 
 
1.9.6. Effects of screening in individuals, health systems and society 
 
 
Policies and practices for screening for type 2 diabetes have profound implications for 
individuals, health systems and the entire society. 
Implications for individuals include the time and other resources necessary to undergo 
the screening tests and any subsequent diagnostic tests, the psychological and social 
effects of the results whether the screening test proves ‘positive’ or ‘negative’ and 
whether or not the diagnosis of type 2 diabetes is subsequently made(144–156),  and 
the adverse effects and costs of earlier treatment of type 2 diabetes or of any preventive 
measures instituted as a result of the individual being found to have diabetes. These 
may include occupational discrimination and/or increased costs or difficulty in obtaining 
insurance. 
The effects on the health system and the entire society are the costs and other 
implications, especially in primary care and support services such as clinical 
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biochemistry of carrying out the screening tests and the necessary confirmatory tests, 
the additional costs of the earlier treatment of those found to have diabetes or to be at 
high risk of developing diabetes or cardiovascular disease in the future and the 
implications of false negative and false positive results which are inevitable given that 
any initial test will be a screening test and not a full diagnostic test and any loss of 
production as a result of the earlier diagnosis of the condition (from absence from work 
or reduced job opportunities, for example) (85). 
 
 
1.9.7. The potential benefits of early detection of type 2 diabetes  
 
 
Improvement in the quality of life and its duration which might result from a reduction in 
the severity and frequency of the immediate effects of diabetes or the prevention or 
delay of its long-term complications and any saving or redistribution of health care 
resources which might be possible as a result of reduced levels of care required for 
diabetes complications (reduced hospital admissions and lengths of stay...) (157-161). 
 
 
 
1.10. Issues in Kosovo 
 
Kosovo as a new country in the Balkans and in a period of transition. As a post-war 
country, Kosovo is facing a number of social, economic, political and especially health 
care related problems.   Health services provided to the population require professional 
and technical expertise and have much room for improvement. 
Health services are organised into three levels: Primary, Secondary and Tertiary level, 
while the Ministry of Health is the highest health authority of the Republic of Kosova. 
Primary health care in Kosovo is considered to be the foundation of the delivery of 
health services and is carried forward mainly by family doctors. Kosovo has about 600 
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family doctors working in family health centres and state health institutions. Whilst in 
post-war Kosovo an emphasis was put on development of Family Medicine, family 
health centres are in many instances poorly equiped.  
The delay in the population Census (the last Census in 2011 was not completed) and 
lack of health insurance system are two of the key obstacles to implementation and 
further development of family medicine in Kosovo. Patients lists have not yet been fully 
compiled for each Family Medicine Centre. The visits are not set in advance and 
electronic medical records have not been implemented as yet. Medical files avaliable in 
some cases are incomplete and/or not maintained properly. Under such conditions, an 
opportunistic screening for diabetes is still difficult to achieve in Kosovo. 
Based on the American Diabetes Association’s (ADA), new diabetes cases can be 
identified by screening patients in at risk groups, the first at risk group are those aged 
above 45 years who should be screened every 3 years (88). Therefore, it is considered 
that this level of screening is possible to do in Kosovo. In this regard, it should be 
emphasized that a situational assessment of diabetes diagnosis in Kosovo has 
previously suggested that 44.8% of cases are diagnosed from clinical symptoms, 29.6% 
from routine visits to medical facilities and 24.6% of diabetes cases in Kosovo are 
diagnosed by chance. Therefore, a pragmatic approach to screening for type 2 diabetes 
could improve  these figures and lead to earlier detection and better prognosis of type 2 
diabetes (162). 
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2. Hypothesis 
 
 
Tools utilized during the screening process are convenient to use in family practice 
setting and the screening methods used in this study are suitable to Kosovo conditions 
and health care situation. 
 
 
 
3. Aims and purpose of the research 
 
 
To determine the prevalence of new cases of diabetes, and impaired fasting glucose 
(IFG) in general practices of Kosovo and to examine the potential relationships of 
diabetes with physical risk factors in Kosovo, where risk factors are more prominent, 
probably because of social and economic reasons.  
Our aim was to investigate the feasibility and performance of very pragmatic system for 
identification of patients with type 2 diabetes and with impaired fasting glycaemia (IFG) 
in the primary health care. This identification system defers from those performed today 
in Western Europe and it was adjusted to the conditions offered by a health system of 
Kosovo.  
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4. Materials and methodology  
 
4.1. Design and settings  
 
In the absence of the lists of patients and also in the absence of electronic medical 
records, we had no opportunity to identify patients with a present risk factor and then to 
call them for a blood glucose test. The only way was to wait for these patients to come 
to the clinics for any other reason. 
This prospective study was planned as a descriptive and cross-sectional study in 5 
family medicine centers in 5 major cities of Kosovo with 5 GP’s who were randomly 
selected to participate in this study during one meeting of Association of Family Doctors 
of Kosovo. GP’s were trained in protocol of study via post or e-mail. 
The project started in July 2012 and continued one year.  
 
 
4.2. Study sample  
 
The population of the study consisted of persons aged 45-70 years who required health 
services for any reason to any of these five ordinances, previously assigned. The 
process of opportunistic screening has been divided in double stratification; first-
evaluation and second-physical and biomedical examination, both during consultation 
phase. 
 
 
4.3. Study protocol 
 
During the first step-evaluation, patients aged 45-70 with known diabetes mellitus were 
detected and excluded from the study. The group of remaining patients aged 45-70 
were first evaluated whether any of them belonged to the persons at risk for type 2 
diabetes. It was considered that at risk for type 2 diabetes were patients who showed at 
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least one of six risk factors for type 2 diabetes, taken from the recommendations of the 
American Diabetes Association (ADA) (88): 
  
1. Positive family history for diabetes (presence of diabetes in the immediate family : 
parents, brothers, sisters) 
2. Arterial Hypertension  (>130/80) 
3. High body mass index (BMI) (>25) 
4. High levels of lipids in blood (LDL>1.8mmol/l ; TG>1.8mmol/l ; HDL<1.3) 
5. Gestational Diabetes (in pregnant women) or the birth of a child with a weight greater 
than 4000gr. 
6. Glycemia measured in the last 3 years with the levels between 6.1- 7.0 mmol/l. 
 
Evaluation was done from patients self reports during the consultation, for: treated 
hypertension and treated lipid metabolism disorders which were defined as receiving 
antyhypertensive and hipolipemic medication, family history of diabetes in parents and 
siblings, delivering a baby with birth weight >4000gr, glycemia measured in the last 3 
years with the levels between 6.1- 7.0 mmol/l and data for overweight. 
Patients with at least one of six risk factors for diabetes mellitus were included in the 
further physical and biomedical examinations.  
 
The capillary blood samples were collected from these patients after an overnight 
fasting (8-12 h) using a plasma calibrated glucometer. To reduce false-negative results 
and to have as convincing results as possible, we repeated the test for each patient also 
in the next day.   
A physical examinations including anthropometric measurements of height, weight, 
waist and hips circumference and blood pressure were taken by the regular practice 
assistants. 
During this time the patients were lightly dressed (the shoes were removed). Weight 
was measured using a calibre scales at 0.1kg and height was measured in the 
31 
 
stadiometer with a head in Frankfort’s plan. The measurements of waist and hips were 
performed by thin hand meter.  
 
1. Body weight (in kg) 
2. Body height  (in cm) 
3. Body mass index  (no decimals) 
4. Waist circumference  (the level of umbilicus) (in cm) 
5. Hips circumference (10 cm. Under the umbilicus) (in cm)  
 
4.4. Assessment of glucose values 
 
Diagnosis of type 2 diabetes and Impaired Fasting Glucose were settled on the basis of 
measured levels of fasting blood glucose screening for two consecutive days based on 
the diagnostic criteria of WHO (5). Patients with only one value in category of IFG or 
undiagnosed type 2 diabetes or those that didn’t responded to the second testing was 
removed from the further statistical analysis. 
Subjects with fasting plasma glucose (FPG)   7 mmol/l were classified as diabetes 
mellitus. An Impaired fasting glucose (IFG) was defined: FPG 6.1 but <7 mmol/l.  
Normoglycemia was considered: FPG <6.1 mmol/l. 
 
 
4.5. The interpretation of fasting blood glucose screening levels 
 
1. If the levels of fasting blood glucose screening were between 6.1 mmol/l and 6.9 
mm/l than this was Impaired Fasting Glucose or prediabetes. The patient was given 
advice about eating habits, physical activity and also an examination was assigned for 
the next year. 
 
2. If the levels of blood glucose screening were 7.0 mmol/l and above the patient was 
diagnosed as Diabetes Mellitus. The patient was given advice about eating habits and 
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physical activity, and oral anti-diabetic medications or insulin was prescribed, besides 
that examinations were assigned as necessary. 
 
 
4.6. Definition of obesity 
 
BMI was calculated as weight (in kilograms) divided by the square of height (in meters). 
Subjects with a BMI 25 kg/m2 but <30 kg/m2 were classified as overweight, and those 
with a BMI 30 kg/m2 were classified as obese.  
Waist circumference was measured with a soft tape on standing subjects midway 
between the lowest rib and the iliac crest and hip circumference was measured with a 
soft tape on standing subject 10 cm below umbilicus. Visceral obesity was defined as a 
waist circumference >80 cm in women and >94 cm in men.  
 
4.7. Definition of hypertension 
 
Systolic blood pressure (sBP) and diastolic blood pressure (dBP) were measured twice 
in the sitting position after a 5-min rest, and the mean was taken in all cases. 
Hypertension was defined as sBP 140 mmHg, dBP 90 mmHg, or the use of 
antihypertensive agents.  
 
Patients were given oral and written information letters explaining the study. Informed 
consent was obtained from each patient prior to their  antropometric measurements. 
 
 
Ethics approval for this study was obtained from the Ethics Committee of the University 
of Zagreb, Faculty of Medicine; Approval number: 04-76/2008-971 and from Ethics 
Committee of the Main Family Medicine Center-Gjilan, Kosovo; Approval number: 04-
1523 
 
33 
 
4.8. Statistical methods 
Data collected were analyzed using the SPSS software. Frequency distributions were 
analyzed and presented as percentage values in case of categorical variables. 
Associations between variables were analysed using the 2 test or Fisher’s exact test 
where appropriate. Stepwise logistic regression analysis was performed to determine 
the association of independent risk factors with type 2 diabetes. Age, sex and family 
history of diabetes, BMI, waist and hip circumference, and hypertension were included 
as covariates.  A P value <0.05 was considered statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
5. Results  
The research conducted in five municipalities within one year period indicated that 
18809 patients underwent a medical check-up, of whom 5334 or 28.4% belonged to the 
age-group of 45-70 years.(Tab.1) 
Tab.1. Structure of patients age group 45-70 years in the total number of patients 
by municipality 
Municipality 
Total number 
of patients 
From them age 
group 45-70 yr 
N % 
FERIZAJ 5977 1544 25.8 
PRIZREN 2336 411 17.6 
PEJA 3927 1380 35.1 
GJILAN 3680 1193 32.4 
MITROVICA 2889 806 27.9 
Total 18809 5334 28.4 
 
From overall number of patients of the age-group of 45-70 years (n=5334) 815 or 15.3% 
were patients who had previously determined diagnosis of Diabetes Mellitus. (Tab.2) 
Tab.2. Structure of patients with Diabetes Mellitus in the total number of patients 
age group 45-70 years by municipality 
Municipality 
Patient of 
age group 
45-70 yr 
From them with 
diabetes mellitus 
N % 
FERIZAJ 1544 113 7.3 
PRIZREN 411 139 33.8 
PEJA 1380 279 20.2 
GJILAN 1193 148 12.4 
MITROVICA 806 136 16.9 
Total 5334 815 15.3 
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From overall number of patients of the age-group of 45-70 years (n=5334) 1346 or 
25.2% were patients with one or more risk factors for Diabetes Mellitus. (Tab.3 and 
Chart.1) 
Tab. 3.  Structure of patients with risk factors for Diabetes Mellitus in the total 
number of patients age group 45-70 years by municipality 
Municipality 
Patient of 
age group 
45-70 yr 
From them with 
risk factors 
N % 
FERIZAJ 1544 329 21.3 
PRIZREN 411 234 56.9 
PEJA 1380 276 20.0 
GJILAN 1193 293 24.6 
MITROVICA 806 214 26.6 
Total 5334 1346 25.2 
 
Chart 1.  Structure of patients in the 5 QMF by the age group, the percentage of cases 
with diabetes mellitus and risk factors 
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Patients who have had one or more risk factors for Diabetes Mellitus were included in 
this research.  Out of 1346 patients with one or more risk factors- 138 or 10.3% of 
whom have carried out only one glycaemia test on empty stomach and they did not 
come for the second test on the next day and therefore since the rules of research 
required to be carried out two tests on empty stomach, they were excluded from the 
research. The other part of patients- a number of 1208 or 89.7% were included in the 
research and they have carried out two glycaemia tests on empty stomach. Out of 1208 
patients included in the research- 447 or 37.0% were men and 761 or 63.0% women, 
i.e. proportion between men and women was 1.7: 1. It happened because women have 
a tendency to ask more often for medical services.  
As per age-groups, we have had patients more of the age-group of 65 and over. They 
also ask more often for medical services. (Tab.4) 
 
Tab. 4.  Patients by age group and gender 
Age group 
Gender 
Total Male Female 
N % N % N % 
45-49 84 18.8 141 18.5 225 18.6 
50-54 80 17.9 187 24.6 267 22.1 
55-59 72 16.1 136 17.9 208 17.2 
60-64 70 15.7 143 18.8 213 17.6 
65+ 141 31.5 154 20.2 295 24.4 
Total N 447 100.0 761 100.0 1208 100.0 
% 37.0 - 63.0 - 100.0 - 
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Chart 2. Structure of patients by gender 
 
 
Patients were asked for six risk factors:  
1. Positive family anamnesis for Diabetes, (presence of Diabetes in the first family 
circle: parents, brothers, sisters) 
2. Treating Hypertension Arterials: TAS≥140 mmHg, TAD≥90 mmHg 
3. High Body Mass Index (BMI) >25 
4. Treating high level of lipids (LDL>1.8mmol/l ; TG>1.8mmol/l ; HDL<1.3) 
5. Gestational Diabetes (during pregnancy) or delivery of the baby with weight over 
4000gr. 
6. Glycaemia measured in the last 3 years with levels ranging between 6.1mmol/- 7.0 
mmol/l. 
 
 
F
63.0%
M
37.0%
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Family anamnesis for diabetes was positive in 358 cases or 29.6% of patients of 
similar gender structure (men 30.6% vs. women 29.0%) and without significant 
difference (P>0.05). (Tab.5) 
Tab. 5.  Patients by positive family anamnesis for Diabetes Mellitus and gender 
   Family history 
Gender 
Total Male Female 
N % N % N % 
Yes 137 30.6 221 29.0 358 29.6 
No 308 68.9 537 70.6 845 70.0 
Don't know 2 0.4 3 0.4 5 0.4 
Total 447 100.0 761 100.0 1208 100.0 
X2-test 
Yes/No 
P=0.575 
  
 
 
At the moment of inclusion in the research, High body weight appeared in 937 cases 
or 77.6% of patients of similar gender structure who were included in this research (men 
75.4% vs. women 78.8%) and without significant difference (P>0.05). (Tab.6) 
 
Tab. 6.  Patients according to the presence of large body weight and gender 
Overweight 
Gender 
Total Male Female 
N % N % N % 
Yes 337 75.4 600 78.8 937 77.6 
No 110 24.6 160 21.0 270 22.4 
Don't know - - 1 0.1 1 0.1 
Total 447 100.0 761 100.0 1208 100.0 
X2-test 
Yes/No 
P=0.174 
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At the moment of inclusion in the research, Hypertension arterial appeared in 823 
cases or 68.1% of patients of similar gender structure who were included in this 
research (men 66.4% vs. women 69.1%) and without significant difference (P>0.05). 
(Tab.7) 
Tab. 7.  Patients according to the presence of arterial hypertension and gender 
Elevated blood 
pressure  
Gender 
Total Male Female 
N % N % N % 
Yes 297 66.4 526 69.1 823 68.1 
No 150 33.6 234 30.7 384 31.8 
Don't know - - 1 0.1 1 0.1 
Total 447 100.0 761 100.0 1208 100.0 
X2-test 
Yes/No 
P=0.350 
  
 
At the moment of inclusion in the research, high level of lipids appeared in 465 cases 
or 38.5% of patients included in the research, but men were in the higher structure than 
women (men 42.5% vs. women 36.1%) but without significant difference (P>0.05). 
(Tab.8) 
Tab. 8.  Patients according to the presence of elevated lipids and gender 
Increased lipids 
Gender 
Total Male Female 
N % N % N % 
Yes 190 42.5 275 36.1 465 38.5 
No 203 45.4 380 49.9 583 48.3 
Don't know 54 12.1 106 13.9 160 13.2 
Total 447 100.0 761 100.0 1208 100.0 
X2-test 
Yes/No 
P=0.052 
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In the last three years glycaemia on empty stomach 6.1-7.0 mmol/L appeared in 
15.1% of participants in the research, 70.3% declared that they did not have it in such 
limit and 14.7% did not know because they did not measure it. Based on the gender, we 
did not get a difference of important statistical significance (P>0.05), (men 15.7 vs. 
women 14.7). (Tab.9) 
Tab. 9.  Patients who in the past three years have had blood glucose 6.1 - 7.0, by 
gender 
In the last three 
years glucose was 
6.1-7.0 
Gender 
Total Male Female 
N % N % N % 
Yes 70 15.7 112 14.7 182 15.1 
No 299 66.9 550 72.3 849 70.3 
Don't know 78 17.4 99 13.0 177 14.7 
Total 447 100.0 761 100.0 1208 100.0 
X2-test 
Yes/No 
P=0.457 
  
 
Out of 761 women included in the research 120 or 15.8% declared that they have 
delivered babies with large birth weight. (Tab.10) 
 
    Tab. 10.  The structure of women who had children with greater weight 
 Large 
children 
Female 
N % 
Yes 120 15.8 
No 632 83.0 
Don't know 9 1.2 
Total 761 100.0 
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All of the persons included in the research were of age 45-70, with average age 57.5 
(SD ± 7.8 years). Average age of men was 58.4 (SD ±8.1 years) whilst average age of 
women was 57.0 (SD ± 7.6 years). Among everage age, by gender, we have got a 
difference of important statistical significance (P<0.01).  Average body weight of the 
participants in the research was 80.0 kg (SD ± 11.5 kg). Average body weight of men 
was 83.6 kg (SD ± 10.9 kg) whilst average body weight of women was 77.9 kg (SD ± 
11.3 kg). In between average body weight, as per the gender, we have got a difference 
of important statistical significance (P<0.0001). Average body height of the participants 
in the research was 166.7 cm (SD ± 7.1 cm). ). Average body height of men was 172.6 
cm (SD ± 5.1 cm) whilst average body height of women was 163.2 cm (SD ± 5.6 cm). 
Among average body height, by gender, we have got a difference of important statistical 
significance (P<0.0001).   
Based on the body mass index women were more obese in comparison with men, 
which is a difference of important statistical significance (P<0.0001). Average value of 
BMI in women was 29.1 (SD ±4.0), range 16-43. Average value of BMI in men was 27.8 
(SD ± 3.1), range of 19 - 40.  
Average value of fasting glycaemia, during the first measuring was 6.0 mmol/L (SD ± 
1.9 mmol/L), range of 3.1 – 23 mmol/L without significant difference between genders, 
(P>0.05). Average value of fasting glycaemia during the second measuring was 5.7 
mmol/L (SD ± 1.6 mmol/L), range of 3.0 – 23.9 mmol/L without significant difference, 
between genders (P>0.05).  
Average value of arterial systolic pressure was 145.0 mmHg (SD ± 23.5 mmHg), 
range 80 – 240 mmHg without significant difference, between genders (P>0.05). 
Average value of arterial diastolic pressure was 89.6 mmHg (SD ± 12.1 mmHg), range 
of 55 – 140 mmHg without significant difference, between genders (P>0.05). (Tab.11) 
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Tab. 11.  General characteristics of patients by gender 
  Male Female Total 
P-value   N 447 761 1208 
Age 
Mean ± 
SD 58.4 ± 8.1 57.0 ± 7.6 57.5 ± 7.8 P=0.004 
Rank 45 - 70 45 - 70 45 - 70 
  
Body Weight 
in kg. 
Mean ± 
SD 83.6 ± 10.9 77.9 ± 11.3 80.0 ± 11.5 P<0.0001 
Rank 53 - 123 45 - 113 45 - 123 
  
Body height 
in cm. 
Mean ± 
SD 172.6 ± 5.1 163.2 ± 5.6 166.7 ± 7.1 P<0.0001 
Rank 140  - 187 143 - 180 140  - 187 
  
BMI 
Mean ± 
SD 27.8 ± 3.1 29.1 ± 4.0 28.7 ± 3.7 P<0.0001 
Rank 19  - 40 16 - 43 16 - 43 
  
Waist 
circumference 
in cm. 
Mean ± 
SD 96.0 ± 11.5 94.6 ±13.7 95.2 ± 12.9 P=0.032 
Rank 63 - 132 50 - 131 50 - 132 
  
 Hips in cm. 
Mean ± 
SD 
104.9 ± 
12.1 
107.2 ± 
14.7 
106.4 ± 
13.8 P=0.0029 
Rank 67 - 143 58 - 160 58 - 160 
  
Fasting 
glucose I 
Mean ± 
SD 6.0 ± 1.9 6.0 ± 1.9 6.0 ± 1.9 P=0.732 
Rank 3.3 - 19 3.1 - 23 3.1 - 23 
  
Fasting 
glucose II 
Mean ± 
SD 5.8 ± 1.7 5.6 ± 1.6 5.7 ± 1.6 P=0.492 
Rank 3.2 - 15.4 3.0 - 23.9 3.0 - 23.9 
  
Systolic blood 
pressure in 
mmHg 
Mean ± 
SD 
144.4 ± 
22.6 
145.3 ± 
24.0 
145.0 ± 
23.5 P=0.718 
Rank 85 - 230 80 - 240 80 - 240 
  
Diastolic 
blood 
pressure in 
mmHg 
Mean ± 
SD 89.0 ± 11.9 89.9 ± 12.2 89.6 ± 12.1 
P=0.473 
Rank 55 - 120 55 - 140 55 - 140 
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Overall number of persons who underwent through screening (n=1208) after two tets of 
glycaemia was 152 or 12.6% (CI:10.8-14.6) of whom were diagnosed with Diabetes 
Mellitus (fasting glycaemia >7.0 mmol/l), 185 or 15.3% (CI:13.4-17.5) with Pre-diabetes 
(fasting glycaemia 6.1 – 6.9 mmol/l). After correction for age, crude prevalence rate of 
patients with diabetes in the total Kosovo population aged 45 to 70 years was 17.2%. 
The yield of opportunistic screening prevalence of type 2 diabetes was 1.9 %. 
 
 In 92 cases or 7.6% value of glycaemia in one measuring was pathological whilst in the 
other was normal and in 779 cases or 64.5% values of glycaemia were normal in two 
tests. In the final results, after two tests in men and women we did not get a difference 
of important statistical significance (P>0.05), occurrence of DM in men was 13.6% whilst 
in women 12.0%. Pre-diabetes occurrence in men was 14.1% whilst in women 16.0%. 
(Tab.12) 
 
 
Tab. 12.  The final result of glycemia by gender 
The final result 
of blood glucose  
Gender 
Total Male Female 
N % N % N % 
Normal 291 65.1 488 64.1 779 64.5 
With one 
abnormal value 32 7.2 60 7.9 92 7.6 
Prediabetes 63 14.1 122 16.0 185 15.3 
Diabetes Mellitus 61 13.6 91 12.0 152 12.6 
Total 447 100.0 761 100.0 1208 100.0 
X2-test P=0.667   
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Pre-diabetes was discovered in 168 cases or 17.3% of persons with overweight and in 
17 cases or 7.1% of persons with normal weight. Diabetes mellitus was discovered in 
133 cases or 13.7% of persons with overweight and in 19 cases or 7.9% of persons with 
normal weight. By X2 test we have got a difference of important statistical significance 
(P<0.0001). Pre-diabetes occurrence and Diabetes Mellitus was much higher in the 
group of persons with overweight. (Tab.13) 
 
Tab. 13. The final result of blood glucose in people with normal weight and those 
with overweight  
The final 
result of 
blood glucose  
Overweight 
Yes No 
N % N % 
Normal 589 60.8 190 79.5 
With one 
abnormal 
value 79 8.2 13 5.4 
Prediabetes 168 17.3 17 7.1 
Diabetes 
Mellitus 133 13.7 19 7.9 
Total 969 100.0 239 100.0 
X2-test P<0.0001 
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Pre-diabetes was discovered in 155 cases or 18.1% of persons with visceral obesity, 
namely in 30 cases or 8.5% of persons without visceral obesity. Diabetes mellitus was 
discovered in 116 cases or 13.6% of persons with visceral obesity, namely in cases 36 
or 10.2% of persons without visceral obesity.  By X2 test we have got a difference of 
important statistical significance (P<0.0001) Pre-diabetes occurrence and Diabetes 
Mellitus was much higher in the group of persons with visceral obesity. (Tab.14) 
 
Tab. 14.  The final result of blood glucose in people with visceral obesity 
The final 
result of 
blood glucose  
Visceral obesity 
Yes No 
N % N % 
Normal 527 61.6 252 71.4 
With one 
abnormal 
value 57 6.7 35 9.9 
Prediabetes 155 18.1 30 8.5 
Diabetes 
Mellitus 116 13.6 36 10.2 
Total 855 100.0 353 100.0 
X2-test P<0.0001 
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358 persons declared that they have positive family anamnesis. Pre-diabetes was 
discovered in 83 cases or 23.2% of persons with positive family anamnesis and in 102 
cases or 12.1% of persons with negative family anamnesis. Diabetes mellitus was 
discovered in 42 cases or 11.7% of persons with positive family anamnesis, namely in 
109 cases or 12.9% of persons with negative family anamnesis. By X2 test we have got 
a difference of important statistical significance (P<0.0001) Pre-diabetes occurrence 
and DM was much higher in the group of persons with positive family anamnesis. 
(Tab.15) 
 
 
Tab. 15.  The final result of blood glucose in people with a positive family history 
The final 
result of 
blood glucose 
Family history 
Yes No 
N % N % 
Normal 207 57.8 568 67.2 
With one 
abnormal 
value 26 7.3 66 7.8 
Prediabetes 83 23.2 102 12.1 
Diabetes 
Mellitus 42 11.7 109 12.9 
Total 358 100.0 845 100.0 
X2-test P<0.0001 
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465 persons have had increased value of lipids. Pre-diabetes was discovered in 83 
cases or 17.8% of persons with increased lipids, namely in 75 cases or 12.9% of 
persons with normal value of lipids.  Diabetes mellitus was discovered in 69 cases or 
14.8% of persons with increased lipids, namely in 58 cases or 9.9% of persons with 
normal value of lipids. By X2 test we have got a difference of important statistical 
significance. (P=0.0049). Pre-diabetes occurrence and DM was much higher in the 
group of persons with increased lipids. (Tab.16) 
 
 
 
 Tab. 16. The final result of blood glucose in people with elevated lipids 
The final 
result of 
blood glucose  
An increased lipids 
Yes No 
N % N % 
Normal 282 60.6 403 69.1 
With one 
abnormal 
value 31 6.7 47 8.1 
Prediabetes 83 17.8 75 12.9 
Diabetes 
Mellitus 69 14.8 58 9.9 
Total 465 100.0 583 100.0 
X2-test P=0.0049 
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There were 823 persons in the group included in screening with arterial hypertension. 
Pre-diabetes was discovered in 121 cases or 14.7% of persons with arterial 
hypertension and in 64 cases or 16.7% of persons had normal arteria tension. 
Diabetes mellitus was discovered in 124 cases or 15.1% of persons with arterial 
hypertension and in 28 cases or 7.3% of persons had normal arterial tension. By X2 
test we have got a difference of important statistical significance (P=0.0021). Pre-
diabetes occurrence and DM was much higher in the group of persons with arterial 
hypertension. (Tab.17) 
 
 
 
Tab. 17. The final result of blood glucose in people with arterial hypertension 
The final 
result of 
blood glucose  
Elevated blood pressure 
Yes No 
N % N % 
Normal 519 63.1 259 67.4 
With one 
abnormal 
value 59 7.2 33 8.6 
Prediabetes 121 14.7 64 16.7 
Diabetes 
Mellitus 124 15.1 28 7.3 
Total 823 100.0 384 100.0 
 
X2-test P=0.0021 
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182 persons included in screening during the last three years had glycaemia 6.1 – 7.0. 
Pre-diabetes was discovered in 57 cases or 31.3% of persons with glycaemia 6.1 – 7.0 
in the last three years and in 101 cases or 11.9% of persons who did not have 
glycaemia 6.1-7.0 mmol/l in the last three years. Diabetes mellitus was discovered in 28 
cases or 15.4% of persons with glycaemia 6.1 – 7.0 in the last three years and in 99 
cases or 11.7% of persons who did not have glycaemia 6.1-7.0 mmol/l in the last three 
years. DM was much higher in the group of persons who did not have glycaemia 6.1-7.0 
mmol/l in the last three years. (Tab.18) 
 
Tab. 18. The final result of blood glucose in people with glycaemia in the last 
three years 6.1 - 7 mmol / L 
The final 
result of 
blood glucose  
In the last three years glucose 
was 6.1-7.0 mmol/L 
Yes No 
N % N % 
Normal 85 46.7 592 69.7 
With one 
abnormal 
value 12 6.6 57 6.7 
Prediabetes 57 31.3 101 11.9 
Diabetes 
Mellitus 28 15.4 99 11.7 
Total 182 100.0 849 100.0 
X2-test P<0.0001 
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Recurrence rate of cases with DM was higher in women who have delivered babies with 
large birth weight (14.2% vs. 11.7%), whereas in cases with pre-diabetes it was higher 
in women who did not deliver babies with large weight (12.5% vs. 16.6%) but without 
significant difference (P>0.05). (Tab.19) 
 
 
Tab. 19. Glycemia final outcome of women who gave birth of large babies 
The final 
result of 
blood glucose  
Large children 
Yes No 
N % N % 
Normal 84 70.0 398 63.0 
With one 
abnormal 
value 4 3.3 55 8.7 
Prediabetes 15 12.5 105 16.6 
Diabetes 
Mellitus 17 14.2 74 11.7 
Total 120 100.0 632 100.0 
X2-test P=0.109 
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All of the cases included in the research have had one or more risk factors for Diabetes 
Mellitus, namely 23.8% of them had one risk factor, 40.2% had two risk factors, 24.7% 
had three risk factors, 9.4% had four risk factors, 1.9% had five risk factors and 0.1% 
had six risks factors for Diabetes Mellitus with similar structure, as per the gender 
(Table 20a and Chart 3). Thus, 36.0% of participants in the research have had three or 
more risk factors (men 38.3% vs. women 34.7%) without significant difference, between 
genders (P>0.05).(Table 20b and Chart 4) 
 
Tab. 20a. Patients based on the number of risk factors and gender 
Risk factors 
Gender 
Total Male Female 
N % N % N % 
1 110 24.6 177 23.3 287 23.8 
2 166 37.1 320 42.0 486 40.2 
3 124 27.7 174 22.9 298 24.7 
4 40 8.9 73 9.6 113 9.4 
5 7 1.6 16 2.1 23 1.9 
6 - - 1 0.1 1 0.1 
Total 447 100.0 761 100.0 1208 100.0 
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Chart 3. Structure of patients according to the number of risk factors 
Tab. 20b. Patients based on the number of risk factors and gender 
Risk factors 
Gender 
Total Male Female 
N % N % N % 
1 110 24.6 177 23.3 287 23.8 
2 166 37.1 320 42.0 486 40.2 
3+ 171 38.3 264 34.7 435 36.0 
Total 447 100.0 761 100.0 1208 100.0 
X2-test P=0.235   
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Chart 4. Structure of the patients by number of risk factors 
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In the cases where final result of glycaemia was normal 30.6% there were 3+ risk 
factors for Diabetes Mellitus, in 34.8% of cases of glycaemia with one normal measuring 
and the other pathological there were 3+ risk factors for Diabetes Mellitus, in 55.1% 
cases of Pre-diabetes there were 3+ risk factors for Diabetes Mellitus and in 41.4% of 
cases of Diabetes Mellitus there were 3+ risk factors for Diabetes Mellitus. (Tab.21) 
 
 
Tab. 21. Glycemia final results according to the number of risk factors 
The final result of 
blood glucose 
Nr. of risk factors 
Total 1 2 3+ 
Normal 
N 222 319 238 779 
% 28.5 40.9 30.6 100.0 
With one 
abnormal value 
N 19 41 32 92 
% 20.7 44.6 34.8 100.0 
Prediabetes 
N 23 60 102 185 
% 12.4 32.4 55.1 100.0 
Diabetes mellitus 
N 23 66 63 152 
% 15.1 43.4 41.4 100.0 
Total 
N 287 486 435 1208 
% 23.8 40.2 36.0 100.0 
X2-test P<0.0001   
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Cases diagnosed with Pre-diabetes and Diabetes mellitus of higher structure had three 
or more risk factors in comparison with cases of normal values of glycaemia which is a 
difference of important statistical significance (P<0.0001). (Chart 5) 
 
 
 
Chart 5. Structure of cases with normal hypoglycaemia, prediabetes and diabetes 
mellitus according to the number of risk factors 
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As seen (Table 22) patients with Pre-diabetes and Diabetes Mellitus of higher structure 
were those of age 65 and over. 
 
 
Tab. 22. Glycemia final results by age group 
Age group 
(year) 
The final result of blood glucose  
Normal 
With one 
abnormal 
value Prediabetes 
Diabetes 
Mellitus 
N % N % N % N % 
45-49 163 20.9 13 14.1 24 13.0 25 16.4 
50-54 185 23.7 20 21.7 35 18.9 27 17.8 
55-59 134 17.2 18 19.6 28 15.1 28 18.4 
60-64 130 16.7 20 21.7 40 21.6 23 15.1 
65+ 167 21.4 21 22.8 58 31.4 49 32.2 
Total 779 100.0 92 100.0 185 100.0 152 100.0 
 
 
56.8 (SD± 7.7 years) was average age of patients whose final results of glycaemia, after 
two tests, was normal, whereas of those who were diagnosed with Pre-diabetes was 
59.3 (SD± 7.8 years) and of those diagnosed with Diabetes Mellitus was 58.9 (SD ± 8.2 
years). By Kruskal Wallis test we have got a difference of important statistical 
significance within average age based on final results of glycaemia (Normal vs. Pre-
diabetes P<0.001; Normal vs. Diabetes Mellitus P<0.05). (Tab.23) 
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Tab. 23. Age parameters of patients according to the final results of glycemia 
Age 
(Year) 
The final result of blood glucose  
Normal 
With one 
abnormal 
value Prediabetes 
Diabetes 
Mellitus 
N 779 92 185 152 
Mean 56.8 58.1 59.3 58.9 
SD 7.7 7.2 7.8 8.2 
Min 45 45 45 45 
Max 70 70 70 70 
Kruskal Wallis 
test P<0.0001 
Dunn's Multiple Comparasion test 
Normal vs. Prediabet P<0.001 
Normal vs. Diabet Mellitus P<0.05 
 
 
 
Average age of participants  was 57.5(SD 7.8 ). By Kruskal Wallis test a significant 
variation in the prevalence of type 2 diabetes, IFG, and normal glicemia  was observed 
within average age: 58.9(SD 8.2), vs 59.3(SD 7.8), vs 56.8(SD 7.8);  P=0.0001. 
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Tab.24.  Multivariate stepwise logistic regression analysis for predictors of type 2 
diabetes. Cumulative risks as prediction for type 2 diabetes . 
Risks OR estimates 
(95%CI) 
P value 
Single overweight  1.88 (1.39- 2.55) <0.0001 
Single family history 1.61 (1.23- 2.10) =0.0006 
Single hypertension  2.01 (1.43- 2.82) <0.0001 
Single hyperlipidemia 1.46 (1.13-1.89) =0.0037 
Hypertension + 
Overweight 
 
1.90 (1.41-2.57) 
<0.0001 
Overweight  + 
 Family history 
 
1.99 (1.49-2.66) 
<0.0001 
Hypertension + 
Overweight + 
Family history 
 
 
2.10 (1.53-2.81) 
 
 
<0.0001 
 
OR:Odds Ratio.95% CI:Confidence interval 
 
Multivariate logistic regression analysis showed that hypertension was the best 
predictor of undiagnosed type 2 diabetes: OR 2.01(CI; 1.43- 2.82), P<0.0001. 
Overweight had significant prediction for undiagnosed type 2 diabetes: OR 1.88(CI;  
1.39- 2.55), P<0.0001. Family history of diabetes had also significant prediction for 
undiagnosed type 2 diabetes: OR 1.61(CI; 1.23- 2.10), P<0.0006. Dyslipidemia was 
poorer predictor of undiagnosed type 2 diabetes: OR 1.46(CI; 1.13-1.89), P<0.0037 
 Antihypertensive treatment was associated with a two fold increased risk of diabetes.  
After adjustment all significant risks the multivariate stepwise logistic regression shows, 
the strongest prediction for type 2 diabetes was risks in fold: hypertension, overweight 
and family history of diabetes. Those, patients  were 2.1 more  likely to have diabetes.  
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6. Discussion 
To our knowledge this study is the first one to report screening of patients for type 2 
diabetes in Kosovo.  
The research conducted in five municipalities within one year period indicated that 
18809 patients underwent a medical check-up, of which 5334 or 28.4% belonged to the 
age-group of 45-70 years.  
From overall number of patients of the age-group of 45-70 years, 815 or 15.3% were 
patients who had previously determined diagnosis of type 2 diabetes. 1208 patients 
were patients with one or more risk factors for type 2 diabetes and they were screened 
for type 2 diabetes in this study.  
The prevalence of diabetes mellitus in the population included in the study was 12.6% 
with 95% CI prevalence in the entire population was 10.8% to 14.6% and IFG 
prevalence of the population involved in the study was 15.3% with 95% CI prevalence in 
the entire population was 13.4% to 17.5%. After correction for age, crude prevalence 
rate of patients with diabetes in the total Kosovo population aged 45 to 70 years was 
17.2%. The yield of opportunistic screening prevalence of T2D was 1.9 %. In 7.6% 
value of glycaemia in one measuring was pathological whilst in the other was normal.  
Average age of participants  was 57.5(SD 7.8 ). By Kruskal Wallis test a significant 
variation in the prevalence of type 2 diabetes, IFG, and normal glicemia  was observed 
within average age: 58.9(SD 8.2), vs 59.3(SD 7.8), vs 56.8(SD 7.8);  P=0.0001. 
No significant variation in the prevalence of type 2 diabetes was observed between 
men’s and women’s (P>0.05), prevalence of type 2 diabetes in men was 13.6% vs 
12.0% in women and the prevalence of IFG in men was 14.1% vs 16.0% in women. 
Women had a lower age (57.0 ± 7.6 vs 58.4 ± 8.1 years; P < 0.004) and a lower body 
weight in kg.(77.9 ± 11.3 vs 83.6 ± 10.9 kg; P = 0.0001), as well as a smaller waist 
circumference (94.6 ± 13.7 vs 96.0 ± 11.5 cm; P < 0.032) than men. Abnormal waist 
circumference was more often found in women than men (50.4 vs 20.3%; P < 0.001) 
and the prevalence rate of overweight (body mass index >25 kg/m2) was higher in 
women than men (54.0 vs 31.2%; P = 0.0001). 
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In this regard, two thirds of screened patients had at least two risk factors for  type 2 
diabetes. Arterial hypertension was diagnosed in majority of screened patients as 
opposed to one third of screened patients who also had abnormal lipid levels.  
Presence of arterial hypertension, abnormal lipid profile and being overweight were olso 
common amongst those found to have pre-diabetes or type 2 diabetes. 
It is interesting to note that patients with prediabetes had a higher number risk factors 
compared to patients who already had developed type 2 diabetes. Therefore, 
suggesting that an early screening process could potentially allow more room for 
clinicians to address type 2 diabetes risk factors. 
Multivariate logistic regression analysis showed that hypertension was the best 
predictor of undiagnosed type 2 diabetes: OR 2.01(CI; 1.43- 2.82), P<0.0001. 
Overweight had significant prediction for undiagnosed type 2 diabetes: OR 1.88(CI;  
1.39- 2.55), P<0.0001. Family history of diabetes had also significant prediction for 
undiagnosed type 2 diabetes: OR 1.61(CI; 1.23- 2.10), P<0.0006. Dyslipidemia was 
poorer predictor of undiagnosed type 2 diabetes: OR 1.46(CI; 1.13-1.89), P<0.0037 
Hypertension commonly co-exists with diabetes as part of metabolic syndrome and it 
commonly begins in the preclinical period of diabetes. Antihypertensive treatment was 
associated with a two to three – fold increased risk of diabetes  
It is known that obesity  and overweight  increases the development of  type 2 diabetes 
and that three quarters overweight adult people are metabolically and  phenotype 
unhealthy obesity  (beta-cell dysfunction, insulin resistance, hyperglycemia) and carry 
risk  for  type 2 diabetes. Also, it is important to note that metabolically healthy obese 
adults show a substantially increased risk of developing type 2 diabetes compared with 
metabolically healthy normal-weight adults. There was a non-significant positive 
association with hiperlipidemia. We can contemplate that prescription of hypolipemic 
drugs or dietary and physical activity are important protective factors against type 2 
diabetes development (182, 184, 185).  
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After adjustment all significant risks the multivariate stepwise logistic regression shows, 
the strongest prediction for type 2 diabetes was risks in fold: hypertension, overweight 
and family history of diabetes. Those, patients  were 2.1 more  likely to have diabetes.  
 
Type 2 diabetes certainly meets many of the screening criteria (163). There is evidence 
that screening for diabetes has an overall benefit with no harm to patients (147).  Many 
international organizations (164,165) have produced guidelines on screening for type 2 
diabetes with information on screening tests and populations, yet none have made 
major recommendations regarding the strategies to approach screening and the method 
of invitation. 
In this regard, due to undetected glucose abnormalities, at time of diagnosis there can 
be a significant percentage of diabetes complications already present. Evidence 
suggest up to 30% of patients have complications at time of diagnosis (172-175). This 
leads to a significant burden not only for patients but also the health care system in 
general. Clinicians could more adequately utilize other therapies such as 
antihypertensives, antihyperlipidaemics and antiplatelet therapies. The ADDITION study 
demonstrated that when compared to routine care, an intervention to promote target-
driven, intensive management of patients with type 2 diabetes detected by screening 
was associated with modest but significant differences in prescribed treatment and 
levels of cardiovascular risk factors at five years (176). 
Screening for a condition is justified only if there is a net benefit in early detection and 
treatment of the condition as compared to its natural clinical presentation. The 
ADDITION study showed declined risks for  cardiovascular disease  in 5 and 10- years 
following diagnosis,  in the group of patients with diabetes detected by screening (177).  
The results reported in this study suggest that a significant number of patients can be 
detected at prediabetes stage by utilizing a ‘pragmatic’ approach of screening.  
This would potentially result in prevention of diabetes development in many of the 
patients screened, prevention of diabetes complications, improved quality of life and 
reduction of health related costs (54). Therefore, results of this study indicate that such 
an approach of screening should be a systematic and continuous process in countries 
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like Kosovo where there may be a lack of means to apply standard type 2 diabetes 
opportunistic screening processes to the general population. Tools utilized during the 
screening process are convenient to use in family practice setting and the screening 
methods used in this study were adopted to Kosovo conditions and health care 
situation.  As such, it has considerable differences compared to Western European 
standards and those of other developed countries around the world.  
Family medicine centers, where the ‘pragmatic’ opportunistic screening for type 2 
diabetes was conducted in this project, represent a suitable primary care setting for type 
2 diabetes screening to take place. However, key challenges reported especially in the 
developing countries should be considered. Countries in transition such as Kosovo, are 
often faced with overbooking and frequent visits by patients which in turn have the 
potential to reduce the available time for performing opportunistic screening for type 2 
diabetes (178). Furthermore, deficiencies in patient documentation and database 
management are also obstacles to implementing opportunistic type 2 diabetes 
screening in transition countries. GPs  need a simple  process of case finding that 
should be performed easily, systematically and continuously, without overprevention 
procedures. It should be performed in country –specific context, using existing health 
resources, without consuming too much time and  additionally burden of consultaton 
(167-170). 
Oportunistic, stepwise approach of screening a patient, using a non-invasive risk 
stratification tool followed by a definite blood test seems the most cost-effective method 
of screening for type 2 diabetes  and those at high risk (171).  
The main strength of the study was the setting. High-risk patients were identified during 
a regular consultation, in the daily routine practice in the local family practice by their 
own family practitioner. Capillary blood samples were taken by the family practitioner, 
without any further support (e.g., from trial nurses). Although patients had to return in a 
fasting state for the capillary glucose measurements, they were highly willing to do so. 
Several diabetes screening studies have been described in the literature. Smith et al. 
(187) undertook an opportunistic diabetes screening study performed in family practice 
using a questionnaire presented to patients who were waiting to see their doctor. Their 
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participation rate was also high (93%), and 43% of patients had at least 2 risk factors. If 
performed continuously or repeated regularly, such an approach might provide more 
complete and up-to-date information on a patient’s risk status in the EMR, improving the 
identification of high-risk patients for screening purposes. 
Greaves et al. (188) showed that identifying patients with type 2 diabetes and IFG using 
data stored in family practice databases was feasible but instead of using an 
opportunistic approach, they invited high-risk patients (those aged >50 years and with a 
body mass index ≥27 kg/m2) to screening clinics run by trained practice nurses. The 
response rate was 61%. Nevertheless, the simple screening system they describe 
would promote efficient use of scarce primary health care resources, especially when 
set up as part of a broader screening program to reduce cardiovascular disease. 
In a cross sectional study in a local family practice, Lawrence et al. (98) showed that 
screening of invited patients whose sole risk factor for diabetes is age older than 45 
years has a low yield. In this group, they found a diabetes prevalence of just 0.2%. 
Among individuals with 1 or more other risk factors, the figure increased to 2.8%.  
In 2007, a population-based screening program for type 2 diabetes was performed in 
the Netherlands. (84)  Although the increase in diabetes prevalence achieved with the 
program (from 6.1% to 7.0% among people aged 50 to 70 years) was good, the 
response to an invitation to glucose testing was 31% and the yield only 1%. The authors 
concluded that opportunistic screening might be more appropriate. 
Other studies concerning screening for type 2 diabetes mainly used questionnaires or 
risk scores to identify at-risk patients, instead of data already present in the EMR. (103, 
189, 190) 
We compare the results of our study with other studies performed recently in Central 
Europe, despite some differences in the structure of the population and the screening 
method used. Detection rate of diabetes and pre-diabetes was higher than reported by 
previous studies. Namely, the prevalence rate of diabetes in Hungarian was 7.47% and 
the prevalence of IFG was 4.39% (179), in Slovakia was 7.0% and the prevalence rate 
of type 2 diabetes in Croatia was 6.1% (180,181). The prevalence rate of IFG in our 
study was much higher (4.39%) than that (11.3%) reported in Croatia (181). 
64 
 
In EUROASPIRE IV, a cross-sectional survey of patients aged 18–80 years with 
coronary artery disease in 24 European countries, 29% had undetected diabetes (182). 
This study has a number of limitations. These includes limited number of patients who 
went through the screening, as opposed to the total number of population at risk who 
could benefit from such a screening. 
A limiting factor was that the visits were not set in advance and electronic medical 
records have not been implemented as yet. Medical files avaliable, in some cases were 
incomplete and not maintained properly so not all risk factors were included at that time. 
We had to ask patients about their risk factors to confirm their status, therefore some of 
the information obtained from patients could have been subjected to recall bias hence 
suggesting a more cautious interpretation of the results.  
A possible limitation was that we used the capillary glucose test rather than the oral 
glucose tolerance test. Although oral glucose tolerance test with fasting and 2-hour 
glucose values has been widely used in the clinical practice for detecting glucose 
intolerance in asymptomatic subjects, an epidemiological survey for screening in 
primary care should be based on fasting blood glucose values only, as it is easier and 
faster to perform, more convenient and acceptable to patients, and less expensive. (82, 
186) 
Nevertheless, given that this is the first study of this kind conducted in Kosovo, we hope 
that it will raise the awaraness of health policymakers, health professionals and patients 
in regards to screening for type 2 diabetes and identifying suitable methods that would 
suit conditions in Kosovo. Further, this study may also provide more insight to countries 
around the world going through similar transition periods and facing financial and 
infrastrucural challenges to implementing standard oppurtunistic type 2 diabetes 
screening. 
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7.Conclusion 
 
1. This study is the first one to report screening of patients for type 2 diabetes in 
Kosovo.   
2. The ‘pragmatic’ opportunistic screening process was suitable for implementation and 
could improve early detection of diabetes in developing countries like Kosovo. 
815 or 15.3% were patients who had previously determined diagnosis of type 2 
diabetes. 
3. This opportunistic screening method for type 2 diabetes in patients of the age-group 
45-70 years, resulted in detection of prevalence of previously known type 2 diabetes 
15.3% 
4. The main findings in this research is detection of unknown number of patients with 
type 2 diabetes and IFG. The prevalence of diabetes mellitus in the study was 12.6% 
(CI:10.8-14.6) and IFG prevalence of the population involved in the study was 15.3% 
(CI:13.4- 17.5).  
5. After correction for age, crude prevalence rate of patients with diabetes in the total 
Kosovo population aged 45 to 70 years was 17.2%. The yield of opportunistic screening 
prevalence of type 2 diabetes was 1.9 %. 
6. Detection rate of diabetes and pre-diabetes was higher than reported by previous 
studies. 
7. Among various risks in univariate analysis hypertension was the best single predictor 
for unknown diabetes type 2 
8. After an adjustment of all significant risks in the multivariate stepwise logistic 
regression, the strongest prediction for undetected diabetes type 2 was risks in fold: 
hypertension, overweight and family history of diabetes mellitus. Those patients were 
2.1 times more likely to have diabetes. 
9. Data’s on the number of previously known diabetes and  the data’s on undiagnosed 
type 2 diabetes have been lacking until our research in Kosovo. We hope that this 
research will raise awareness of the decision-making instances so; in a near future we 
can undertake a survey at a much larger scale, at the national level.  
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8. Sazetak na hrvatskom jeziku 
 
Uvod: Probir za secernu bolest tipa 2 u obiteljskoj medicini u zemljama u razvoju ostaje 
i dalje izazov. Zbog toga se istrazuje najprakticnija metoda u svakodnevnom radu. 
 
Ciljevi: Istraziti prevalenciju neotkrivene secerne bolesti i ostecene glukoze nataste u 
ambulantama obiteljske medicine na Kosovu i testirati najoptimalniji model 
oportunistickog probira za otkrivanje ovih pacijenata 
 
Mjesto: Pet ordinacija obiteljske medicine na Kosovu 
 
Metode: Istrazivali smo metodu oportunistickog probira secerne bolesti u ordinaciji 
obiteljske medicine. Probirom su obuhvaceni svi pacijenti u dobi 45-70 godina sa 
najmanje jednim poznatim cimbenikom rizika koji su iz bilo kojeg razloga posjetili svog 
lijecnika. 
 
Rezultati: Probirom je obuhvaceno 1208 pacijenata. Otkrivena su 152(12.6%) pacijenta 
sa secernom bolesti te 185(15.3%) sa predijabetesom 
Statisticki znacajni rizicni faktori su (p<0.05); prekomjerna tjelesna tezina (77.6%), 
hipertenzija (68.1%) I hiperlipidemija. Vecina pacijenata (76.2%) je imala dva faktora 
rizika, dok je 36% imalo tri faktora rizika.     
 
Zakljucak: Ova studija je pokazala da je metoda oportunistickog probira prikladna za 
implementaciju u ordinacije obiteljske medicine u zemljama u razvoju, poput Kosova. 
Otkriven je znacajan broj pacijenata sa secernom bolescu i predijabetesom koji su 
takoder imali prekomjernu tjelesnu tezinu, hipertenziju i hiperlipidemiju.  
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9. Abstract  
 
 
Background. Screening for type 2 diabetes mellitus in primary care in developing 
contries remains a challenge, therefore pragmatic models of opportunistic screening 
should be explored. 
 
Objective: To determine the prevalence of new cases of diabetes and impaired fasting 
glucose in general practices of Kosovo and investigate the feasibility and performance 
of a pragmatic system for identifying patients with these two conditions. 
 
Settings: Five general practices in Kosovo.   
 
Methods: The study utilized an opportunistic screening programme for type 2 diabetes 
detectection in primary care.  All patients with at least one risk for undiagnosed type 2 
diabetes, aged  45-70, who  attended to general practices for any reason were 
screened.  Fasting capillary blood glucose was measured on two independent days. 
Additionally, anthropometric measurements were also performed  
 
Results: A total of 1208 patients were screened for type 2 diabetes. There were 152 
(12.6%) undiagnosed type 2 diabetes and 185 (15.3%) prediabetes patients  
Significant prediction factors (p<0.05) were; overweight (77.6%), hypertension (68.1%) 
and hyperlipidemia (38.5%). The majority of patients (76.2%) had two risk factors and 
36% had three risk factors  
 
Conclusions: The ‘pragmatic’ opportunistic screening process in this study was 
suitable for implementation in transition countries like Kosovo and resulted in detection 
of significant number of patients with pre-diabetes and type 2 diabetes who were also 
overweight, had hypertension and hyperlipidaemia 
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